Uncategorized
Medicare Coverage-In-Clinical-Trials Policy For Alzheimer’s Drugs Could Stifle Access For Years
GAP President John Dwyer spoke to Pink Sheet about the CMS NCD proposal. The Centers for Medicare and Medicaid Service’s proposal to allow Medicare to pay for amyloid-directed monoclonal antibody drugs for Alzheimer’s only when they are used in randomized controlled clinical trials could significantly curtail access to the drugs for at least four years, […]
The Encouraging Progress of Diagnostics and Data Sharing in Dementia
Microsoft and Gates Ventures founder, Bill Gates, mentions GAP’s Bio-Hermes study to the World Dementia Council. We’ve all heard the statistics: Today, nearly 55 million people suffer from Alzheimer’s disease or related dementias. According to the WHO, dementia is the fastest growing burden on healthcare systems and the seventh leading cause of death worldwide. Its […]
x
ALZForum: PrevenTRON and Beyond
x
ALZForum: PrevenTRON and Beyond
x
ALZForum: PrevenTRON and Beyond
x
ALZForum: PrevenTRON and Beyond